Enable JavaScript to visit this website.
Skip directly to content

PFIZER REACHES AGREEMENT WITH CANADA TO SUPPLY UP TO 125 MILLION DOSES OF THE PFIZER-BIONTECH COVID-19 VACCINE IN 2022 – 2023

23/04/21

KIRKLAND, QC, April 23, 2021 — Pfizer Canada today announced it has reached an agreement with the Government of Canada to supply up to 125 million doses of the Pfizer-BioNTech COVID-19 vaccine in 2022 and 2023, with options to supply up to 60 million additional doses in 2024.

As part of this agreement, Pfizer will supply 35 million doses in 2022, with options for the purchase of up to 30 million additional doses. In 2023, under the terms of the agreement, Pfizer will supply 30 million doses with options for the purchase of up to 30 million additional doses. The agreement also allows for potential purchase of doses in 2024. The terms of the agreement also include potential adapted versions of the vaccine.

“We’re very pleased to continue our partnership with the Government of Canada to bring this vaccine to Canadians,” said Fabien Paquette, Vaccines Lead, Pfizer Canada. “We look forward to building on the 48 million doses that we are supplying this year alone.”

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

AUTHORIZED USE IN CANADA:
Pfizer-BioNTech COVID-19 Vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. Pfizer-BioNTech COVID-19 Vaccine must be injected intramuscularly only.

The use of Pfizer-BioNTech COVID-19 Vaccine is permitted under an interim authorization delivered in accordance with section 5 of the COVID-19 Interim order (IO). Patients should be advised of the nature of the authorization. The interim authorization is associated with Terms and Conditions that need to be met by the Market Authorization Holder to ascertain the continued quality, safety and efficacy of the product. For further information on authorization under this pathway, please refer to Health Canada’s IO Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

About Pfizer Canada

Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified healthcare portfolio includes some of the world's best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedInFacebookTwitter or YouTube.

-30-

For more information:

Pfizer Canada Corporate Affairs
1-866-9-PFIZER (1 866 973-4937)
[email protected]